vTv Therapeutics Inc. VTVT
vTv Therapeutics Inc. (Nasdaq: VTVT) is an endocrine/women's health drug developer. Its lead program, Cadisegliatin (TTP399), is in Phase 3 for Type 1 diabetes (as adjunctive therapy to insulin). Its next catalyst on record is Cadisegliatin CATT1: Topline results from Phase 3 CATT1 study (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Cadisegliatin CATT1 — Topline results from Phase 3 CATT1 study (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Cadisegliatin | Type 1 diabetes (adjunctive to insulin) | small molecule | Phase 3 |
| Cadisegliatin | Type 1 diabetes with hybrid closed-loop insulin delivery systems | small molecule | Phase 2 |
| Cadisegliatin | Type 2 diabetes (adjunctive to insulin) | small molecule | Phase 2 |
| HPP737 | Not specified (PDE4 inhibitor) | small molecule | Pre-clinical |
| Azeliragon | Not specified | small molecule | Pre-clinical |
Recent results and decisions
- Oct 31, 2026completed enrollment Phase 3 CATT1 trial evaluating cadisegliatin for type 1 diabetes completed enrollment with 166 participants randomized.
Completing enrollment in the Phase 3 CATT1 trial is a significant milestone for vTv, and we look forward to reporting topline results in mid 2027.
Filing - Oct 27, 2026started First participant randomized in Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in type 1 diabetes patients using hybrid closed-loop insulin delivery systems.
On October 27, 2026, the Company announced that the first participant had been randomized in its Phase 2a Hybrid CATT1 pilot study.
Filing - Oct 6, 2026n/a FDA granted Orphan Drug Designation to HPPD for sickle cell disease.
On October 6, 2026, the FDA granted Orphan Drug Designation to HPPD (HPP8668), an oral, first-in-class Nrf2/Bach1 modulator being investigated as a treatment for sickle cell disease.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.